Regulation (EU) 2017/745

Regulation (EU) 2017/745
User:Verdy p, User:-xfi-, User:Paddu, User:Nightstallion, User:Funakoshi, User:J · Public domain · source
Title	Regulation (EU) 2017/745
Type	Regulation
Adopted	2017-04-05
Jurisdiction	European Union
Status	in force

Regulation (EU) 2017/745 is a European Union legislative act governing medical devices and in vitro diagnostic instruments across the European Union, replacing earlier frameworks to harmonize product safety, clinical evidence, and market access. It updates obligations for manufacturers, Notified body (European Union), and economic operators while aligning with international standards such as International Organization for Standardization and frameworks influenced by the World Health Organization and Council of the European Union. The regulation interacts with directives and statutes from institutions like the European Commission, European Parliament, and European Council.

Background and scope

The regulation was adopted amid debates involving the European Commission, European Parliament, and stakeholders including European Medicines Agency, World Health Organization, and national authorities such as Federal Institute for Drugs and Medical Devices and Agence Nationale de Sécurité du Médicament et des Produits de Santé. It expanded the scope relative to the Medical Devices Directive 93/42/EEC and Active Implantable Medical Devices Directive 90/385/EEC, addressing incidents like the Breast implant scandal and concerns raised by Paul Thacker and investigative reports in outlets such as The BMJ and The Lancet. The instrument covers a broad array of products, from devices used in Johns Hopkins Hospital and Mayo Clinic settings to consumables distributed via firms like Medtronic and Johnson & Johnson.

Key provisions and requirements

The regulation establishes requirements for quality management systems comparable to ISO 13485 and clinical evaluation processes mirroring guidance from International Medical Device Regulators Forum. It mandates post-market surveillance obligations similar to practices at Food and Drug Administration and reporting mechanisms coordinated with entities like European Databank on Medical Devices and national competent authorities such as Paul-Ehrlich-Institut. Provisions address unique device identification influenced by systems like Global Unique Device Identification Database and require technical documentation reviewed by Notified body (European Union) and, in some cases, national competent authorities including Bundesinstitut für Arzneimittel und Medizinprodukte.

Classification and conformity assessment

Classification rules expand categories established under Medical Devices Directive 93/42/EEC and incorporate risk-based approaches analogous to those in International Electrotechnical Commission standards and guidance from European Committee for Standardization. The regulation clarifies classification for implantable devices used in institutions like Cleveland Clinic and point-of-care instruments used in networks such as NHS England. Conformity assessment procedures involve Notified body (European Union), clinical investigation oversight similar to processes managed by European Medicines Agency, and technical documentation aligned with standards from International Organization for Standardization and European Medicines Agency guidances.

Implementation and transitional provisions

Transitional timelines required coordination between the European Commission, national competent authorities, and notified bodies like TÜV SÜD and BSI Group, affecting legacy devices certified under directives such as Active Implantable Medical Devices Directive 90/385/EEC. Delays and reallocations prompted responses from industry associations including MedTech Europe and national ministries such as Ministry of Health (France), with implementation influenced by events like the COVID-19 pandemic which affected clinical investigation capacity at centers like Karolinska Institutet and supply chains involving GE Healthcare and Siemens Healthineers.

Impact on stakeholders and industry

Manufacturers from conglomerates such as Siemens Healthineers, Philips, Roche, and Abbott Laboratories faced increased compliance costs and resource allocations for technical documentation, clinical evidence, and notified body audits. Hospitals such as Charité – Universitätsmedizin Berlin and procurement agencies like Crown Commercial Service adjusted purchasing and inventory strategies, while patient organizations including European Patients' Forum and professional societies like European Society of Cardiology engaged in guidance development. The regulation altered market dynamics impacting small and medium enterprises represented by European Association of Medical Devices Notified Bodies and venture capital flows in regions like Silicon Valley and Eindhoven.

Enforcement and market surveillance

Enforcement responsibilities rest with national competent authorities such as Agence nationale de sécurité du médicament et des produits de santé and Medicines and Healthcare products Regulatory Agency, coordinated by the European Commission and databases like European Databank on Medical Devices. Market surveillance activities echo practices in United States Food and Drug Administration inspections and international cooperation through forums like International Medical Device Regulators Forum. Sanctions, vigilance reporting, and corrective actions involve notified bodies, manufacturers, and distributors, with oversight tied to legal frameworks influenced by Treaty on the Functioning of the European Union and judgments from the Court of Justice of the European Union.

Category:European Union regulations